Richard M Szydlo

List of Publications by Year
in descending order

220	10,977	30070 54	32842 100
papers	citations	h-index	g-index

220	220	220	9255
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic application of transcripts associated with antibody-mediated rejection in kidney transplant biopsies. Nephrology Dialysis Transplantation, 2022, 37, 1576-1584.	0.7	6
2	Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UKâ€‰â€”â€‰a multicentre observational study. British Journal of Haematology, 2022, 196, 79-94.	2.5	8
3	Impact of major bleeding and thrombosis on 180â€day survival in patients with severe COVIDâ€19 supported with venoâ€venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. British Journal of Haematology, 2022, 196, 566-576.	2.5	27
4	Assessment of quantitative polymerase chain reaction for BCRâ€“ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact ofÂtechnology?. British Journal of Haematology, 2022, 197, 52-62.	2.5	7
5	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood, 2022, 139, 1939-1953.	1.4	15
6	Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Transplantation and Cellular Therapy, 2022, 28, 183.e1-183.e8.	1.2	0
7	Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. Leukemia, 2021, 35, 2424-2430.	7.2	8
8	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. Bone Marrow Transplantation, 2021, 56, 2690-2696.	2.4	6
9	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684659.	3.9	14
10	Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. Science Translational Medicine, 2021, 13, eabf0113.	12.4	32
11	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, .	3.0	14
12	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 193, 346-355.	2.5	18
13	Glue versus mechanical mesh fixation in laparoscopic inguinal hernia repair: meta-analysis and trial sequential analysis of randomized clinical trials. British Journal of Surgery, 2021, 108, 14-23.	0.3	13
14	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. Leukemia, 2020, 34, 667-670.	7.2	10
15	Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening. Bone Marrow Transplantation, 2020, 55, 1290-1296.	2.4	1
16	Effect of directâ€acting oral anticoagulants (DOACs) on bleeding and blood product usage in cardiac surgery compared to warfarin and controls. British Journal of Haematology, 2020, 190, 284-293.	2.5	0
17	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. Bone Marrow Transplantation, 2020, 55, 1975-1984.	2.4	8
18	Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica, 2020, 105, 2639-2646.	3.5	17

#	Article	IF	Citations
19	Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. Haematologica, 2020, 105, 2651-2654.	3.5	42
20	Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia. Blood, 2020, 136, 1-2.	1.4	0
21	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2167-2171.	2.0	69
22	A novel Haematoâ€oncology Frailty (HOF) score tool predicts survival in over 80s with Multiple Myeloma. British Journal of Haematology, 2019, 187, e72-e75.	2.5	4
23	A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, e270-e271.	2.0	1
24	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica, 2019, 104, 2400-2409.	3.5	37
25	Impaired cellular and humoral immunity is a feature of Diamondâ€Blackfan anaemia; experience of 107 unselected cases in the United Kingdom. British Journal of Haematology, 2019, 186, 321-326.	2.5	16
26	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica, 2019, 104, 2206-2214.	3.5	10
27	Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, 443-450.	2.0	84
28	FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. Scientific Reports, 2019, 9, 1505.	3.3	96
29	Mesenchymal stromal cells for acute graftâ€versusâ€host disease: response at 1Âweek predicts probability of survival. British Journal of Haematology, 2019, 185, 89-92.	2.5	28
30	Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. British Journal of Haematology, 2019, 184, 808-816.	2.5	30
31	Impact of route and adequacy of nutritional intake on outcomes ofÂallogeneic haematopoietic cell transplantation for haematologic malignancies. Clinical Nutrition, 2019, 38, 738-744.	5.0	37
32	Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). Blood, 2019, 134, 26-26.	1.4	8
33	Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors. Blood, 2019, 134, 3249-3249.	1.4	0
34	Better HLA Matching as Revealed Only by Next Generation Sequencing Technology Results in Superior Overall Survival Post-Allogeneic Haematopoietic Cell Transplantation with Unrelated Donors. Biology of Blood and Marrow Transplantation, 2018, 24, S63-S64.	2.0	7
35	Câ€reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of earlyâ€and longâ€term mortality. British Journal of Haematology, 2018, 180, 889-892.	2.5	6
36	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <scp>EBMT</scp>. British Journal of Haematology, 2018, 182, 418-422.	2.5	28

#	Article	IF	Citations
37	Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients. Blood, 2018, 132, 3007-3007.	1.4	4
38	Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk. Blood, 2018, 132, 4650-4650.	1.4	0
39	Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 204-204.	1.4	0
40	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. American Journal of Hematology, 2017, 92, 359-366.	4.1	24
41	Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. Bone Marrow Transplantation, 2017, 52, 717-725.	2.4	45
42	E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica, 2017, 102, e297-e299.	3.5	42
43	Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1729-1735.	2.0	2
44	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. Breast Cancer Research and Treatment, 2017, 166, 527-539.	2.5	24
45	Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. Bone Marrow Transplantation, 2017, 52, 1599-1601.	2.4	14
46	Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Frontiers in Immunology, 2017, 8, 1937.	4.8	38
47	Mild chronic graftâ€versusâ€host disease may alleviate poor prognosis associated with <scp>FLT</scp>3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. European Journal of Haematology, 2016, 96, 236-244.	2.2	10
48	The finer points of writing and refereeing scientific articles. British Journal of Haematology, 2016, 172, 350-359.	2.5	5
49	Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. Transfusion, 2016, 56, 1052-1057.	1.6	16
50	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Blood, 2016, 128, 2226-2226.	1.4	1
51	Haemopoietic Stem Cell Transplantation for Diamond Blackfan Anaemia Leads to Early and Sustained Engraftment with Good Long-Term Outcomes, but Has an Increased Risk of Gut Toxicity and Lung GvHD. Blood, 2016, 128, 2679-2679.	1.4	1
52	The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions. Blood, 2016, 128, 5987-5987.	1.4	1
53	The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.. Journal of Clinical Oncology, 2016, 34, e23140-e23140.	1.6	1
54	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. Blood, 2016, 128, 3411-3411.	1.4	0

#	Article	IF	Citations
55	Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Matched and Single Antigen Mismatched Unrelated Bone Marrow Transplantation in Haemoglobinopathies Is Feasible and Leads to Early and Sustanined Engraftment with No Long-Term Toxicity or GvHD. Blood, 2016, 128, 2468-2468.	1.4	3
56	Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in Î² Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD. Blood, 2016, 128, 1283-1283.	1.4	0
57	A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. Genome Medicine, 2015, 7, 128.	8.2	7
58	Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 350-356.	2.0	11
59	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplantation, 2015, 50, 209-215.	2.4	108
60	Cancer-Selective Targeting of the NF-Î²B Survival Pathway in Multiple Myeloma with the GADD45Î²/MKK7 Inhibitor, DTP3. Blood, 2015, 126, 868-868.	1.4	3
61	Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology. Blood, 2015, 126, 4481-4481.	1.4	0
62	Female donors and donors who are lighter than their recipient are less likely to meet the <scp>CD</scp>34+ cell dose requested for peripheral blood stem cell transplantation. Transfusion, 2014, 54, 2953-2960.	1.6	20
63	Night-time immobilization of the distal interphalangeal joint reduces pain and extension deformity in hand osteoarthritis. Rheumatology, 2014, 53, 1142-1149.	1.9	17
64	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8592-8592.	1.6	0
65	Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation. Blood, 2014, 124, 4557-4557.	1.4	0
66	Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2013, 48, 1395-1400.	2.4	37
67	Night-time splinting of the distal interphalangeal joint reduces pain and improves extension at the joint: results from the splint-OA study. Osteoarthritis and Cartilage, 2013, 21, S25-S26.	1.3	1
68	Use of thromboelastography to assess the combined role of pregnancy and obesity on coagulation: a prospective study. International Journal of Obstetric Anesthesia, 2013, 22, 113-118.	0.4	21
69	Capillary zone electrophoresis for haemoglobinopathy diagnosis. Journal of Clinical Pathology, 2013, 66, 29-39.	2.0	38
70	Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplantation, 2013, 48, 1324-1328.	2.4	11
71	Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leukemia and Lymphoma, 2013, 54, 2200-2204.	1.3	39
72	Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads To High Rates Of Long-Term Engraftment and Low Toxicity Enabling The Use Of Mismatched and Unrelated Donors For Transplantation In Haemoglobinopathies. Blood, 2013, 122, 2041-2041.	1.4	0

#	Article	IF	Citations
73	The Depth Of â€˜Completeâ€™ Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy. Blood, 2013, 122, 5201-5201.	1.4	0
74	Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2012, 30, 232-238.	1.6	449
75	Prognostic Factors for Survival post Surgery for Patients with Gastrointestinal Stromal Tumors. European Surgical Research, 2012, 48, 3-9.	1.3	8
76	Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood, 2012, 119, 1838-1843.	1.4	68
77	Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. Blood, 2012, 120, 5087-5088.	1.4	12
78	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 5030-5036.	1.4	129
79	EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure. Biology of Blood and Marrow Transplantation, 2012, 18, 235-240.	2.0	25
80	Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC. Biology of Blood and Marrow Transplantation, 2012, 18, 289-294.	2.0	51
81	Impact of Hemochromatosis Gene (HFE) Polymorphisms and Iron Overload on Outcome of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2012, 18, S210.	2.0	1
82	Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive nonâ€Hodgkin lymphoma. Hematological Oncology, 2012, 30, 214-215.	1.7	3
83	Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. British Journal of Haematology, 2012, 157, 125-127.	2.5	8
84	Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.. Blood, 2012, 120, 2789-2789.	1.4	0
85	A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. Blood, 2012, 120, 2555-2555.	1.4	0
86	High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplantation, 2011, 46, 364-367.	2.4	16
87	Risk Score Predicts Outcome of Second Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S155.	2.0	0
88	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011, 117, 3733-3736.	1.4	292
89	Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica, 2011, 96, 1779-1782.	3.5	20
90	Three decades of transplantation for chronic myeloid leukemia: what have we learned?. Blood, 2011, 117, 755-763.	1.4	103

#	Article	IF	Citations
91	Duplex quantitative PCR for molecular monitoring of BCRâ€ABL1â€associated hematological malignancies. American Journal of Hematology, 2011, 86, 313-315.	4.1	10
92	LACEâ€conditioned autologous stem cell transplantation for relapsed or refractory diffuse large Bâ€cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematological Oncology, 2011, 29, 75-80.	1.7	9
93	Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. Journal of Clinical Pathology, 2011, 64, 829-831.	2.0	5
94	Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica, 2011, 96, 307-314.	3.5	113
95	The Diagnostic Value of CD1d Expression in a Large Cohort of Patients With B-Cell Chronic Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2011, 136, 400-408.	0.7	25
96	Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood, 2011, 118, 1680-1680.	1.4	3
97	Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT. Annals of Transplantation, 2011, 16, 47-54.	0.9	7
98	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,. Blood, 2011, 118, 4052-4052.	1.4	0
99	Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,. Blood, 2011, 118, 3753-3753.	1.4	0
100	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1945-1945.	1.4	0
101	Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagulation and Fibrinolysis, 2010, 21, 201-206.	1.0	60
102	Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica, 2010, 95, 922-927.	3.5	24
103	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood, 2010, 115, 4018-4020.	1.4	56
104	Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood, 2010, 116, 2033-2039.	1.4	43
105	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood, 2010, 116, 5497-5500.	1.4	65
106	Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 2010, 95, 224-231.	3.5	112
107	Fetoâ€maternal haemorrhage does not account for the differences in cord blood volume obtained from Black and Asian versus Caucasoid donors. British Journal of Haematology, 2010, 148, 951-953.	2.5	0
108	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. Journal of Clinical Oncology, 2010, 28, 2381-2388.	1.6	802

#	Article	IF	Citations
109	Reply to Z.S. Lalmahomed et al. Journal of Clinical Oncology, 2010, 28, e290-e290.	1.6	1
110	Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 28-34.	2.0	70
111	Sign of the Zodiac as a Predictor of Survival for Recipients of an Allogeneic Stem Cell Transplant for Chronic Myeloid Leukaemia (CML): An Artificial Association. Transplantation Proceedings, 2010, 42, 3312-3315.	0.6	6
112	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. Blood, 2010, 116, 2539-2539.	1.4	1
113	Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.. Blood, 2010, 116, 3414-3414.	1.4	6
114	Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs. Blood, 2010, 116, 2274-2274.	1.4	1
115	2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. Blood, 2010, 116, 677-677.	1.4	0
116	Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. Blood, 2010, 116, 3515-3515.	1.4	0
117	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 3488-3488.	1.4	0
118	The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs). Blood, 2010, 116, 3576-3576.	1.4	0
119	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica, 2009, 94, 1399-1406.	3.5	34
120	Unique Localization of Circulating Tumor Cells in Patients With Hepatic Metastases. Journal of Clinical Oncology, 2009, 27, 6160-6165.	1.6	88
121	Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma. Cancer Genetics and Cytogenetics, 2009, 194, 48-52.	1.0	3
122	Does a rise in the BCRâ€ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. British Journal of Haematology, 2009, 145, 373-375.	2.5	27
123	Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood, 2009, 113, 4521-4524.	1.4	47
124	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.. Blood, 2009, 114, 3290-3290.	1.4	10
125	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.. Blood, 2009, 114, 3248-3248.	1.4	0
126	The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.. Blood, 2009, 114, 2147-2147.	1.4	0

#	Article	IF	Citations
127	Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3392-3392.	1.4	4
128	Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT.. Blood, 2009, 114, 3309-3309.	1.4	26
129	Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.. Blood, 2009, 114, 2840-2840.	1.4	0
130	Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. Journal of Clinical Oncology, 2008, 26, 3358-3363.	1.6	524
131	Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression. Journal of Clinical Oncology, 2008, 26, 4806-4813.	1.6	171
132	Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. Blood, 2008, 112, 2163-2166.	1.4	21
133	Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies. Blood, 2008, 112, 2378-2378.	1.4	4
134	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.. Blood, 2008, 112, 970-970.	1.4	0
135	Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT. Blood, 2008, 112, 4301-4301.	1.4	0
136	Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2008, 112, 3319-3319.	1.4	0
137	The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood, 2007, 110, 380-383.	1.4	126
138	Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab. Transplant Immunology, 2007, 18, 179-185.	1.2	5
139	Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation. Leukemia Research, 2007, 31, 1433-1436.	0.8	10
140	LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplantation, 2007, 39, 41-47.	2.4	27
141	The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplantation, 2007, 40, 983-988.	2.4	54
142	Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia, 2007, 21, 943-948.	7.2	46
143	Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. British Journal of Haematology, 2007, 136, 833-836.	2.5	25
144	C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant.. Blood, 2007, 110, 3005-3005.	1.4	7

#	Article	IF	Citations
145	Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2007, 110, 464-464.	1.4	0
146	Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood, 2006, 107, 205-212.	1.4	127
147	Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood, 2006, 107, 4171-4176.	1.4	119
148	Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2006, 37, 937-943.	2.4	6
149	Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplantation, 2006, 38, 799-805.	2.4	59
150	Serum concentrations of Dickkopfâ€1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer, 2006, 119, 1728-1731.	5.1	153
151	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood, 2005, 105, 4532-4539.	1.4	228
152	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood, 2005, 106, 2969-2976.	1.4	163
153	Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood, 2005, 105, 4893-4894.	1.4	36
154	Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia, 2005, 19, 507-512.	7.2	94
155	The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 2005, 19, 1969-1976.	7.2	99
156	The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. Journal of Clinical Pathology, 2005, 58, 715-721.	2.0	49
157	Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.. Blood, 2005, 106, 1804-1804.	1.4	2
158	Long Term Survival Analysis after High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation for Treatment of AL Amyloidosis: A Single Centre Experience.. Blood, 2005, 106, 5503-5503.	1.4	0
159	Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.. Blood, 2005, 106, 1984-1984.	1.4	0
160	Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 2004, 126, 686-689.	2.5	93
161	Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature Genetics, 2004, 36, 447-449.	21.4	425
162	Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplantation, 2004, 33, 1225-1229.	2.4	24

#	Article	IF	Citations
163	Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia, 2004, 18, 1420-1426.	7.2	61
164	The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland. British Journal of Haematology, 2004, 124, 499-503.	2.5	10
165	IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood, 2004, 103, 717-724.	1.4	43
166	Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma. International Journal of Cancer, 2003, 106, 455-457.	5.1	84
167	Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 120, 74-79.	2.5	56
168	Bone marrow transplantation for Î²-thalassaemia major: the UK experience in two paediatric centres. British Journal of Haematology, 2003, 120, 289-295.	2.5	85
169	Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. British Journal of Haematology, 2003, 122, 424-429.	2.5	9
170	Serum levels of macrophage inflammatory protein-1 alpha (MIP-1Î±) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology, 2003, 123, 106-109.	2.5	147
171	Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia, 2003, 17, 1448-1453.	7.2	65
172	Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet, The, 2003, 362, 617-619.	13.7	35
173	Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood, 2003, 102, 1217-1223.	1.4	114
174	Soluble receptor activator of nuclear factor ÎºB ligandâ€“osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 2003, 102, 1064-1069.	1.4	386
175	Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism. Blood, 2003, 102, 2173-2179.	1.4	36
176	Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood, 2002, 99, 2304-2309.	1.4	71
177	Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood, 2002, 100, 2673-2673.	1.4	16
178	Survival after bone-marrow transplantation. Lancet, The, 2002, 359, 888-889.	13.7	1
179	A study of cytokine gene polymorphisms and protein secretion in renal transplantation. Transplant Immunology, 2001, 8, 237-244.	1.2	49
180	Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet, The, 2001, 358, 271-276.	13.7	325

#	Article	IF	Citations
181	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood, 2001, 98, 2879-2880.	1.4	38
182	Early detection of BCR-ABL transcripts by quantitative reverse transcriptaseâ€“polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2001, 97, 1560-1565.	1.4	154
183	Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. British Journal of Haematology, 2001, 112, 228-236.	2.5	101
184	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal of Haematology, 2001, 115, 569-574.	2.5	66
185	Surviving survival analysis. Bone Marrow Transplantation, 2001, 28, 907-907.	2.4	3
186	Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. The Hematology Journal, 2001, 2, 265-272.	1.4	9
187	Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia. , 2000, 27, 278-284.		10
188	Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. Statistics in Medicine, 2000, 19, 3005-3016.	1.6	39
189	High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. British Journal of Haematology, 2000, 108, 769-777.	2.5	13
190	Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve. British Journal of Haematology, 2000, 109, 148-152.	2.5	39
191	Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplantation, 2000, 25, 143-146.	2.4	7
192	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood, 2000, 96, 86-90.	1.4	62
193	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	1.4	243
194	Cytokine secretion in mixed lymphocyte culture: a prognostic indicator of renal allograft rejection in addition to HLA mismatching. Transplant Immunology, 2000, 8, 109-114.	1.2	21
195	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood, 2000, 96, 86-90.	1.4	2
196	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	1.4	0
197	Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia. Leukemia and Lymphoma, 1999, 32, 299-307.	1.3	5
198	A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplantation, 1999, 23, 705-709.	2.4	18

#	Article	IF	Citations
199	Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant. Experimental Hematology, 1999, 27, 1477-1486.	0.4	116
200	CT and MRI Manifestations of Central Nervous System Infection following Allogeneic Bone Marrow Transplantation. Clinical Radiology, 1999, 54, 390-397.	1.1	44
201	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplantation, 1998, 21, 1055-1061.	2.4	67
202	INTERLEUKIN 3 (IL-3), BUT NOT STEM CELL FACTOR (SCF) INCREASES SELF-RENEWAL BY HUMAN ERYTHROID BURST-FORMING UNITS (BFU-E) IN VITRO. Cytokine, 1998, 10, 49-54.	3.2	15
203	Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.. Journal of Clinical Oncology, 1997, 15, 1767-1777.	1.6	440
204	Factors influencing the outcome of bone marrow transplants using unrelated donors. Immunological Reviews, 1997, 157, 153-166.	6.0	82
205	Paranasal sinusitis following allogeneic bone marrow transplant. Bone Marrow Transplantation, 1997, 19, 55-59.	2.4	53
206	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 1997, 20, 553-560.	2.4	134
207	Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. British Journal of Haematology, 1997, 99, 30-35.	2.5	56
208	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. British Journal of Haematology, 1997, 99, 945-950.	2.5	72
209	Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16â€year period. British Journal of Haematology, 1997, 96, 111-116.	2.5	212
210	Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: Evidence for primary or secondary humoral responses depending on donor immune status. , 1996, 49, 61-65.		21
211	CYTOTOXIC T LYMPHOCYTE PRECURSOR FREQUENCY ANALYSES IN BONE MARROW TRANSPLANTATION WITH VOLUNTEER UNRELATED DONORS VALUE IN DONOR SELECTION. Transplantation, 1995, 59, 1302-1307.	1.0	53
212	IN VITRO CYTOKINE PROFILES AND THEIR RELEVANCE TO REJECTION FOLLOWING RENAL TRANSPLANTATION. Transplantation, 1995, 60, 703-706.	1.0	30
213	CYTOTOXIC T LYMPHOCYTE PRECURSOR FREQUENCY ANALYSES IN BONE MARROW TRANSPLANTATION WITH VOLUNTEER UNRELATED DONORS VALUE IN DONOR SELECTION. Transplantation, 1995, 59, 1302-1307.	1.0	14
214	Phenotypic Characterization of Normal and CML CD34â€“Positive Cells: Only the Most Primitive CML Progenitors Include Ph-neg Cells. Leukemia and Lymphoma, 1993, 11, 51-61.	1.3	2
215	Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]. Blood, 1993, 82, 2235-2238.	1.4	165
216	Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]. Blood, 1993, 82, 2235-2238.	1.4	39

#	Article	IF	Citations
217	HLAâ€identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. British Journal of Haematology, 1992, 81, 383-390.	2.5	44
218	Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY. British Journal of Haematology, 1991, 79, 567-574.	2.5	101
219	The relationship between the Physicochemical properties of pyrethroid insecticides and their speed of neurotoxic action. Pest Management Science, 1985, 16, 673-683.	0.4	3
220	Impact of aspirin on bleeding and blood product usage in offâ€pump and onâ€pump coronary artery bypass graft surgery. EJHaem, 0, , .	1.0	0